Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's agitation medications.
A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form of dronabinol, an FDA-approved synthetic version of THC (the main ingredient in marijuana), reduces agitation in Alzheimer's patients by an average of 30%.
The researchers say that compared to current treatments for agitation, such as antipsychotics, dronabinol produced similar calming effects without adverse results such as delirium or seizures.
Results of the eight-year clinical trial were presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, on Sept. 26."These new findings represent eight years of work dedicated to people who have Alzheimer's as well as their caregivers," says Paul Rosenberg, M.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and co-principal investigator for this study. "Agitation is one of the most distressing symptoms of Alzheimer's dementia, and we are pleased to make positive strides forward in the treatment of these patients."
Alzheimer's Agitation and the Need for New Treatments
Alzheimer's disease is the most common neurodegenerative disease in the United States, with an estimated 6.7 million cases in Americans age 65 and older, according to the National Institutes of Health. This number is predicted to grow to 13.8 million by 2060. Agitation is difficult to manage. It is defined as excess motor activity (pacing or repetitive movements), verbal aggression, and/or physical aggression. An estimated 40% of people with Alzheimer's develop agitation.
Although mild agitation can sometimes be moderated by behavioral intervention, in moderate to severe cases, some form of medication is typically required to manage symptoms and provide relief for caregivers."It is the agitation, not the memory loss, that often drives individuals with dementia to the emergency department and long-term-care facilities," says Brent Forester, M.D., psychiatrist-in-chief and chairman of the Department of Psychiatry at Tufts Medical Center and co-principal investigator on the study. "Dronabinol has the potential to both reduce health care costs and make an important, positive impact on caregivers' mental and physical health."
In the new study, researchers recruited 75 patients with severe Alzheimer's agitation across five clinical sites, including 35 admitted to The Johns Hopkins Hospital between March 2017 and May 2024. To qualify, patients had to have a formal clinical diagnosis of Alzheimer's disease and show at least one major symptom of agitation for at least two weeks. Prior to treatment, patients were tested for agitation using the Pittsburgh Agitation Scale (PAS) and the Neuropsychiatric Inventory Agitation/Aggression subscale (NPI-C).
The PAS scores agitation from 0 to 4, with 4 being the most agitated. The NPI-C provides a brief assessment of neuropsychiatric symptoms including delusions, hallucinations, anxiety/depression, and other factors. Baseline scores were acquired from caregivers at the onset of the trial.
Participants were then randomly selected to get either 5 milligrams of dronabinol in pill form or a placebo in pill form twice daily for three weeks, and then retested using the PAS and NPI-C.
Future Research and Cautions
Results from the dronabinol group show an average PAS starting value of 9.68 and an end value of 7.26 after three weeks, a 30% decrease compared to the scores in the placebo group which did not change. Additionally, dronabinol was well tolerated by patients compared to current treatments for agitation."Results like this are encouraging. We are thrilled that FDA-approved dronabinol was robustly effective and appeared safe for treatment of agitation," says Rosenberg. "This adds another tool in our efforts to improve the care of our loved ones with Alzheimer's disease."
The researchers say they plan longer-term studies of dronabinol for Alzheimer's disease, as well as expanded sample sizes. They also hope to continue to explore other ways medical cannabis can benefit both patients and caregivers.
Dronabinol is a synthetic form of THC, the psychoactive main ingredient in cannabis (marijuana). The drug was approved by the U.S. Food and Drug Administration in 1985 to treat loss of appetite in patients with HIV/AIDS, and is currently prescribed to treat nausea and vomiting in those undergoing cancer chemotherapy.
The investigators caution that their current study results are not intended to encourage or inform the use of other forms of medical marijuana available in 38 states and the District of Columbia.
Meeting: International Psychogeriatric Association conference
Co-investigators include Halima Amjad, Haroon Burhanullah and Milap Nowrangi at the Johns Hopkins University School of Medicine, Marc Agronin at Miami Jewish Health, and James Wilkins and David Harper at McLean Hospital.
The study was funded by a grant from the National Institute of Aging at the National Institutes of Health.
News
Why More People in Their 30s Are Suddenly Getting Colon Cancer
A major Swiss study found that colorectal cancer is becoming increasingly common in adults under 50, even as rates decline in older age groups. Researchers in Switzerland have identified a concerning trend: while colorectal [...]
Researchers Compare MS Models to Human Tissue in Search for Better Therapies
Researchers identified key differences between two widely used multiple sclerosis models, showing how each can better study myelin damage, immune responses, and repair. The findings may improve efforts to develop treatments that restore lost [...]
Scientists Discover Genetic “Off Switch” That Supercharges CAR T Cells Against Cancer
A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single gene-regulating protein. CAR T-cell therapy is widely seen as a breakthrough in personalized cancer [...]
New Vitamin B12-Based Therapy Could Change How Brain Cancer Is Treated
Researchers have identified a vitamin B12–based compound that appears capable of crossing the blood–brain barrier and selectively accumulating in glioblastoma tissue. For decades, one of the biggest problems in brain cancer treatment has had [...]
Simple Fiber Supplement Cuts Knee Arthritis Pain in Just 6 Weeks, Study Finds
A daily inulin supplement may help reduce knee osteoarthritis pain while revealing a possible link between gut health, muscle function, and pain sensitivity. For millions of people living with knee osteoarthritis, managing chronic pain [...]
This Common Vitamin May Help Stop Prediabetes From Turning Into Diabetes
Vitamin D may help prevent type 2 diabetes in people with specific genetic variations, offering a possible path toward personalized diabetes prevention. More than 40% of U.S. adults have prediabetes, a condition in which [...]
Ebola, hantavirus: Is the world prepared for the next pandemic?
Funding cuts to health research and a growing antivaccine movement are making it harder than ever to respond to viruses. The World Health Organization (WHO) has declared that an Ebola outbreak in Uganda and [...]
May 2026 Healthcare News and Trends: Market Signals That Matter
Artificial intelligence is dominating headlines, telehealth has settled into a new normal, and digital health continues to promise transformation. However, much of what is being discussed in healthcare today reflects potential rather than reality. [...]
Scientists Rewire Donor Stem Cells To Outsmart Aggressive Blood Cancers
Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful cancer-targeting immunotherapies. For patients with highly aggressive blood cancers, stem cell transplantation can offer a rare chance at [...]
Recent Digital Health Trends, Insights and News – May 2026
Last month marked continued progress as digital health moves into its next phase — from AI expanding into drug discovery and core infrastructure to new federal pathways accelerating device access and home-based care. Together, [...]
Cancer Mystery Solved: Scientists Discover How Melanoma Becomes “Immortal”
Scientists have uncovered a previously overlooked mechanism that may help melanoma cells become effectively “immortal.” Cancer cells face a major problem before they can become deadly: They have to figure out how to stop [...]
How Visual Neurons Organize Thousands of Synaptic Inputs
Summary: A new study uncovered the organizational rules that determine how neurons in the primary visual cortex process information. By imaging both the cell bodies (soma) and the individual synapses (on dendritic spines) of [...]
Scientists Just Found a Surprising Way To Destroy “Forever Chemicals”
Scientists have uncovered a new mechanism that may help break down highly persistent PFAS pollutants. PFAS have earned the nickname “forever chemicals” for a reason. These industrial compounds are so chemically durable that they [...]
Scientists Discover Cheap Material That Kills Deadly Superbugs
A new sulfur-rich antimicrobial polymer shows strong effectiveness against fungal and bacterial pathogens and may offer an affordable solution to antimicrobial resistance. Antimicrobial resistance is creating growing challenges for both healthcare and food production, [...]
What to Know About Cicada, or BA.3.2, the Latest SARS-CoV-2 Variant Under Monitoring
Like periodical cicadas, the insects for which it is nicknamed, SARS-CoV-2 Omicron subvariant BA.3.2 is only just beginning to emerge after lying low for an extended period since it first appeared. Although it was [...]
Scientists Say This Simple Supplement May Actually Reverse Heart Disease
Scientists in Japan say a common supplement may actually help “unclog” certain diseased heart arteries from the inside out. A simple food supplement sold in Japan may have helped reverse a dangerous form of [...]
